Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study

Last updated: March 6, 2025
Sponsor: Latin American Cooperative Oncology Group
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05776147
LACOG 0122
  • Ages > 18
  • Female

Study Summary

The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women over 18 years old;

  • Diagnosis of breast cancer of any molecular subtype;

  • Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively;

  • Treated from December/2019 onward;

  • With clinical and treatment data available in medical records.

Exclusion

Exclusion Criteria:

  • The protocol does not provide exclusion criteria.

Study Design

Total Participants: 400
Study Start date:
November 09, 2023
Estimated Completion Date:
June 01, 2025

Study Description

All patients diagnosed with breast cancer who meet the eligibility criteria at participating centers will be included. Data will be collected from medical records at selected centers. Data collection will start from the location activation date. Data from up to 500 patients are expected to be collected at centers across Brazil.

Patients recruited for this study will be identified at participating centers. Data on clinical, demographic and socioeconomic variables will be collected, as well as data on treatments performed and outcomes.

The patient data sources will be the patients' medical records. Patients will continue to receive treatment and clinical evaluations for their illness as determined by their medical team, in accordance with the standards of care and usual clinical practice at each center. No intervention is proposed in this study.

Connect with a study center

  • ICC - Instituto do Câncer do Ceará

    Fortaleza, Ceará 60.430-230
    Brazil

    Active - Recruiting

  • Hospital Sírio-Libanês DF

    Brasília, Distrito Federal 70.200-730
    Brazil

    Site Not Available

  • Hospital Márcio Cunha da Fundação São Francisco Xavier (HMC-FSFX)

    Ipatinga, Minas Gerais 35.160-158
    Brazil

    Site Not Available

  • Oncominas - Clínica de Oncologia no Sul de Minas

    Pouso Alegre, Minas Gerais 37.554-216
    Brazil

    Active - Recruiting

  • Real Hospital Português de Beneficência em Pernambuco

    Recife, Pernambuco 50.030-230
    Brazil

    Site Not Available

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP

    Ribeirão Preto, São Paulo 14.015-010
    Brazil

    Active - Recruiting

  • Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ)

    Rio De Janeiro, 22.793-080
    Brazil

    Active - Recruiting

  • A.C. Camargo Cancer Center

    São Paulo, 01.509-001
    Brazil

    Active - Recruiting

  • BP - A Beneficência Portuguesa de São Paulo

    São Paulo, 01.323-030
    Brazil

    Active - Recruiting

  • HAOC - Hospital Alemão Oswaldo Cruz

    São Paulo, 01.323-020
    Brazil

    Active - Recruiting

  • Hospital Sírio-Libanês SP

    São Paulo, 01.308-050
    Brazil

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.